Agenus secures $22 million mortgage and plans operational reorientation; jump stocks

Agenus Inc. is an immuno-oncology (IO) company. which targets cancer and infectious diseases with a pipeline of immunological agents. He specializes in developing treatments that aim to strengthen the body’s immune system against cancer and disease. Its portfolio includes immunomodulatory antibodies, adoptive cell therapies (through MiNK Therapeutics, Inc.) and vaccine adjuvants (through SaponiQx, Inc.). Its primary focus is IO, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform . Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and enhanced human T lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (an enhanced Fc receptor blocking antibody) 1 of programmed death (PD).-1)). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators and tumor microenvironment conditioning agents.